SAB Biotherapeutics Inc — Cash Flow (NASDAQ:SABS) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Cash from operating activities —3.76 M-23.46 M-25.12 M-34.29 M -37.53 M Cash from investing activities —-10.94 M-2.09 M-152.7 K-11.96 M -110.67 M Cash from financing activities —34.12 M1.05 M66.77 M-1.17 M 168.56 M Free cash flow —-7.19 M-25.63 M-25.32 M-34.63 M -37.59 M

Haberler

UBS, SAB Biotherapeutics hissesini diyabet ilacı potansiyeli nedeniyle Al tavsiyesiyle başlattı

SAB Biotherapeutics stock initiated with Buy rating at UBS on diabetes drug potential

Guggenheim, SAB Biotherapeutics hissesini Tip 1 Diyabet potansiyeli nedeniyle Al tavsiyesi ile başlattı

Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential

SAB Biotherapeutics, iki yönetim kurulu üyesinin istifasının ardından kurul büyüklüğünü azalttı

SAB Biotherapeutics reduces board size following resignations of two directors

SAB Biotherapeutics hissedarları sermaye planı değişikliğini ve B Serisi dönüşüm teklifini onayladı

SAB Biotherapeutics shareholders approve equity plan amendment and Series B conversion proposal

SAB Biotherapeutics hissesi, olumlu diyabet tedavi verileriyle H.C. Wainwright’ta Al notunu korudu

SAB Biotherapeutics stock maintains Buy rating at H.C. Wainwright on positive diabetes treatment data

Chardan Capital lowers SAB Biotherapeutics stock price target to $12 from $20

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release